20 Nov, 2020

PREDICTIVE FACTORS FOR LOSS OF RESPONSE TO ANTI-TNF IN CROHN’S DISEASE

Byanca Rossetti Moreira dos SANTOS
Carlos Henrique Marques dos SANTOS
Vitória Rossetti Moreira dos SANTOS
Claudia Yanina Garcia TORREZ
Daniel PALOMARES-JUNIOR
DOI: 10.1590/0102-672020200002e1522
Share this article

Background:

Anti-TNF drugs are a fundamental part of the treatment of Crohn’s disease (CD), so identifying factors related to loss of response is of great importance in clinical practice.

Aim:

Identify potential factors related to loss of response to anti-TNF agents in Crohn’s disease patients.

Methods:

This is a prospective study of CD patients attending a specialized outpatient clinic using a specific form, including patients with more than one year of follow-up on anti-TNF (Infliximab, Adalimumab or Certolizumab pegol). The information obtained was tabulated and analyzed to identify possible reasons for the loss of response to anti-TNF agents; results were submitted to statistical analysis by chi-square teste considering significant p<0.05.

Results:

Sixty-four patients were included, most of them females (56.3%), predominant age group between 26 and 55 years, of whom 25 required optimization, 23 remained in remission with the usual dose and interval, and 16 required switch; most of those who needed switch had hematological problems such as anemia and/or had already undergone surgical treatment for CD.

Conclusions:

Anemia and prior CD surgery have been linked to loss of anti-TNF response.


. . .
Indexed in:
Follow us!
ABCD – BRAZILIAN ARCHIVES OF DIGESTIVE SURGERY is a periodic with a single annual volume in continuous publication, official organ of the Brazilian College of Digestive Surgery - CBCD.

Developed by Surya MKT